We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ascletis Pharma

News List

First HBV patient dosed in phase IIa clinical trial of ASC22 pharmaceutical-business-review
August 19, 2020
Ascletis Pharma announces the dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody.
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients prnasia
March 25, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today the first clinical study using Ganovo®(danoprevir) to treat naive and experienced COVID-19 patients was published in medRxiv.
Ascletis Pharma to develop Alphamab’s viral diseases drug in China pharmaceutical-technology
January 16, 2019
Ascletis Pharma has signed an exclusive licensing agreement with Suzhou Alphamab to develop an investigational candidate, KN035, for the treatment of viral diseases such as hepatitis B in Greater China....
WHO HCV Guidelines recommends Ascletis' Ravidasvir biospectrumasia
August 10, 2018
Ravidasvir is a next-generation, best-in-class and pan-genotypic HCV NS5A inhibitor with a high genetic barrier to resistance